506 related articles for article (PubMed ID: 23274666)
41. Identification of Genotype 2 HCV in Serotype-1 Hepatitis C Patients Unresponsive to Daclatasvir plus Asunaprevir Treatment.
Inoue J; Kanno A; Wakui Y; Miura M; Kobayashi T; Morosawa T; Kogure T; Kakazu E; Ninomiya M; Fujisaka Y; Umetsu T; Takai S; Nakamura T; Shimosegawa T
Tohoku J Exp Med; 2017 Jan; 241(1):21-28. PubMed ID: 28049871
[TBL] [Abstract][Full Text] [Related]
42. Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C Virus NS5B polymerase.
Lemm JA; Liu M; Gentles RG; Ding M; Voss S; Pelosi LA; Wang YK; Rigat KL; Mosure KW; Bender JA; Knipe JO; Colonno R; Meanwell NA; Kadow JF; Santone KS; Roberts SB; Gao M
Antimicrob Agents Chemother; 2014 Jun; 58(6):3485-95. PubMed ID: 24733465
[TBL] [Abstract][Full Text] [Related]
43. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227).
Seiwert SD; Andrews SW; Jiang Y; Serebryany V; Tan H; Kossen K; Rajagopalan PT; Misialek S; Stevens SK; Stoycheva A; Hong J; Lim SR; Qin X; Rieger R; Condroski KR; Zhang H; Do MG; Lemieux C; Hingorani GP; Hartley DP; Josey JA; Pan L; Beigelman L; Blatt LM
Antimicrob Agents Chemother; 2008 Dec; 52(12):4432-41. PubMed ID: 18824605
[TBL] [Abstract][Full Text] [Related]
44. Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from
Sahuc ME; Sahli R; Rivière C; Pène V; Lavie M; Vandeputte A; Brodin P; Rosenberg AR; Dubuisson J; Ksouri R; Rouillé Y; Sahpaz S; Séron K
J Virol; 2019 May; 93(10):. PubMed ID: 30842319
[TBL] [Abstract][Full Text] [Related]
45. Resistance analysis and characterization of NITD008 as an adenosine analog inhibitor against hepatitis C virus.
Qing J; Luo R; Wang Y; Nong J; Wu M; Shao Y; Tang R; Yu X; Yin Z; Sun Y
Antiviral Res; 2016 Feb; 126():43-54. PubMed ID: 26724382
[TBL] [Abstract][Full Text] [Related]
46. Discovery of hepatitis C virus NS5A inhibitors as a new class of anti-HCV therapy.
Lee C
Arch Pharm Res; 2011 Sep; 34(9):1403-7. PubMed ID: 21975800
[TBL] [Abstract][Full Text] [Related]
47. Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden.
Lindström I; Kjellin M; Palanisamy N; Bondeson K; Wesslén L; Lannergard A; Lennerstrand J
Infect Dis (Lond); 2015 Aug; 47(8):555-62. PubMed ID: 25851241
[TBL] [Abstract][Full Text] [Related]
48. In vitro activity of daclatasvir on hepatitis C virus genotype 3 NS5A.
Wang C; Valera L; Jia L; Kirk MJ; Gao M; Fridell RA
Antimicrob Agents Chemother; 2013 Jan; 57(1):611-3. PubMed ID: 23089758
[TBL] [Abstract][Full Text] [Related]
49. Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.
Dietz J; Susser S; Vermehren J; Peiffer KH; Grammatikos G; Berger A; Ferenci P; Buti M; Müllhaupt B; Hunyady B; Hinrichsen H; Mauss S; Petersen J; Buggisch P; Felten G; Hüppe D; Knecht G; Lutz T; Schott E; Berg C; Spengler U; von Hahn T; Berg T; Zeuzem S; Sarrazin C;
Gastroenterology; 2018 Mar; 154(4):976-988.e4. PubMed ID: 29146520
[TBL] [Abstract][Full Text] [Related]
50. Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir.
McPhee F; Friborg J; Levine S; Chen C; Falk P; Yu F; Hernandez D; Lee MS; Chaniewski S; Sheaffer AK; Pasquinelli C
Antimicrob Agents Chemother; 2012 Jul; 56(7):3670-81. PubMed ID: 22508297
[TBL] [Abstract][Full Text] [Related]
51. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir.
Karino Y; Toyota J; Ikeda K; Suzuki F; Chayama K; Kawakami Y; Ishikawa H; Watanabe H; Hernandez D; Yu F; McPhee F; Kumada H
J Hepatol; 2013 Apr; 58(4):646-54. PubMed ID: 23178977
[TBL] [Abstract][Full Text] [Related]
52. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.
Pérez AB; Chueca N; García-Deltoro M; Martínez-Sapiña AM; Lara-Pérez MM; García-Bujalance S; Aldámiz-Echevarría T; Vera-Méndez FJ; Pineda JA; Casado M; Pascasio JM; Salmerón J; Alados-Arboledas JC; Poyato A; Téllez F; Rivero-Juárez A; Merino D; Vivancos-Gallego MJ; Rosales-Zábal JM; García F;
J Hepatol; 2019 Nov; 71(5):876-888. PubMed ID: 31279901
[TBL] [Abstract][Full Text] [Related]
53. [Significance of hepatitis C virus baseline polymorphism during the antiviral therapy].
Tornai I
Orv Hetil; 2015 May; 156(21):849-54. PubMed ID: 26038992
[TBL] [Abstract][Full Text] [Related]
54. Inhibition of protease-inhibitor-resistant hepatitis C virus replicons and infectious virus by intracellular intrabodies.
Gal-Tanamy M; Zemel R; Bachmatov L; Jangra RK; Shapira A; Villanueva RA; Yi M; Lemon SM; Benhar I; Tur-Kaspa R
Antiviral Res; 2010 Oct; 88(1):95-106. PubMed ID: 20705106
[TBL] [Abstract][Full Text] [Related]
55. Fast hepatitis C virus RNA elimination and NS5A redistribution by NS5A inhibitors studied by a multiplex assay approach.
Liu D; Ji J; Ndongwe TP; Michailidis E; Rice CM; Ralston R; Sarafianos SG
Antimicrob Agents Chemother; 2015; 59(6):3482-92. PubMed ID: 25845863
[TBL] [Abstract][Full Text] [Related]
56. A novel HCV NS3 protease mutation selected by combination treatment of the protease inhibitor boceprevir and NS5B polymerase inhibitors.
Chase R; Skelton A; Xia E; Curry S; Liu S; McMonagle P; Huang HC; Tong X
Antiviral Res; 2009 Nov; 84(2):178-84. PubMed ID: 19747948
[TBL] [Abstract][Full Text] [Related]
57. Asunaprevir-containing regimens for the treatment of hepatitis C virus infection.
Yang SS; Kao JH
Expert Rev Gastroenterol Hepatol; 2015 Jan; 9(1):9-20. PubMed ID: 25174254
[TBL] [Abstract][Full Text] [Related]
58. Preclinical Profile and Clinical Efficacy of a Novel Hepatitis C Virus NS5A Inhibitor, EDP-239.
Owens CM; Brasher BB; Polemeropoulos A; Rhodin MH; McAllister N; Peng X; Wang C; Ying L; Cao H; Lawitz E; Poordad F; Rondon J; Box TD; Zeuzem S; Buggisch P; Lin K; Qiu YL; Jiang L; Colvin R; Or YS
Antimicrob Agents Chemother; 2016 Oct; 60(10):6207-15. PubMed ID: 27503640
[TBL] [Abstract][Full Text] [Related]
59. HA1077 displays synergistic activity with daclatasvir against hepatitis C virus and suppresses the emergence of NS5A resistance-associated substitutions in mice.
Lee SH; Moon JS; Pak BY; Kim GW; Lee W; Cho H; Kim S; Kim SJ; Oh JW
Sci Rep; 2018 Aug; 8(1):12469. PubMed ID: 30127498
[TBL] [Abstract][Full Text] [Related]
60. HCV NS5A inhibitors disrupt replication factory formation: a novel mechanism of antiviral action.
Eyre NS; Beard MR
Gastroenterology; 2014 Nov; 147(5):959-62. PubMed ID: 25265576
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
